Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Neoplasms 4 Advanced Cancer 4 Lymphoma, Non-Hodgkin 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Lymphoma, Large B-Cell, Diffuse 2 Liver Neoplasms 2 Hodgkin Disease 2 Various Advanced Cancer 1 Uveal Melanoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms by Site 1 Microsatellite Unstable Colorectal Cancer 1 Melanoma, Cutaneous Malignant 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Burkitt Lymphoma 1 Advanced Solid Tumors 1

Interventions

pembrolizumab 3 relatlimab 1 lifileucel 1 dabrafenib 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma, Cutaneous Malignant × relatlimab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡